Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes
暂无分享,去创建一个
J. Hsia | S. Grundy | P. Barter | D. Waters | P. Deedwania | A. Breazna | J. Larosa | J. Shepherd | J. Fruchart | S. Haffner | R. Carmena
[1] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[2] D. Hunninghake,et al. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. , 2004, Journal of the American College of Cardiology.
[3] Henrik Vestergaard,et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. , 2004, Archives of internal medicine.
[4] Paul Schoenhagen,et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.
[5] D. Waters,et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? , 2004, The American journal of cardiology.
[6] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[7] Thomas Weber,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[8] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2004, European heart journal.
[9] A. Keech,et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. , 2003, Diabetes care.
[10] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .
[11] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[12] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[13] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[14] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[15] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[16] 武井泉,et al. United Kingdom Prospective Diabetes Study (UKPDS) , 1999 .
[17] B. Davis,et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.
[18] R. Holman,et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.
[19] V. Salomaa,et al. Impact of Diabetes on Mortality After the First Myocardial Infarction , 1998, Diabetes Care.
[20] P. O S I T I O N S T A T E M E N T. Management of Dyslipidemia in Adults With Diabetes , 1998, Diabetes Care.
[21] Terje R Pedersen,et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.
[22] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[23] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[24] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[25] J. Neaton,et al. Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.